Skip to main content
Caplight Logo









RongCan Biotech

RongCan Biotech

Private
ShanghaiHealthcare & Life Scienceshttp://rc-rna.com/

Last Round

Series A

Extension

Sep 28, 2025

Total Funding Raised

$14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

RongCan Biotech is a biotechnology company that develops nucleic acid-based therapeutics, including mRNA vaccines and LNP-based delivery systems.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

mRNA therapeuticsLNPlipid nanoparticlerna drug developmentnucleic acid medicinerna platformsiRNA therapeuticsmRNA vaccinedrug discovery platformgene therapyCMCchemistry, manufacturing, and controlsbiotech CDMOdrug delivery technologybiopharma partner

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

RongCan Biotech Comparables

Compare RongCan Biotech with similar companies based on industry and business-model similarity.

RongCan Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shenzhen MagicRNA Biotechnology Co., Ltd.
89%
Starna Therapeutics
87%
Immorna Biotherapeutics
86%

RongCan Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionSep 28, 2025
Series ADec 6, 2023
Early FundingApr 6, 2023
Early FundingNov 21, 2022
AngelJun 15, 2021

RongCan Biotech Investors

Notable investors and investment history

RongCan Biotech investors
InvestorRounds
Lilly Asia VenturesAngel
Guangzhou Yuexiu Industrial Investment Fund ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 28, 2025

    Completed a Series A Extension round.

  • Dec 6, 2023

    $14M round led by Guangzhou Yuexiu Industrial Investment Fund Management

RongCan Biotech Filings

Explore SEC and related filing metadata, where available.

RongCan Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about RongCan Biotech's valuation, stock price, and market status.

Is RongCan Biotech a public or private company?

RongCan Biotech is a private company.

What is the current stock price of RongCan Biotech?

RongCan Biotech is a private company with no public stock price. No recent secondary market data is available.

How much is RongCan Biotech worth (valuation)?

Valuation information for RongCan Biotech is not publicly available.

Can I buy RongCan Biotech stock?

RongCan Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was RongCan Biotech's last funding round?

RongCan Biotech's most recent funding round was Series A Extension on September 28, 2025.

Who are the main investors in RongCan Biotech?

Key investors in RongCan Biotech include Guangzhou Yuexiu Industrial Investment Fund Management.

Will RongCan Biotech IPO soon?

No public IPO plans have been announced for RongCan Biotech.

How can I track RongCan Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor RongCan Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Year Founded2020
Last FundingSep 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?